UNLABELLED: In a prospective multicentre study of bloodstream infection (BSI) from November 01, 2007 to July 31, 2010, seven paediatric cancer centres (PCC) from Germany and one from Switzerland included 770 paediatric cancer patients (58% males; median age 8.3 years, interquartile range (IQR) 3.8-14.8 years) comprising 153,193 individual days of surveillance (in- and outpatient days during intensive treatment). Broviac catheters were used in 63% of all patients and Ports in 20%. One hundred forty-two patients (18%; 95% CI 16 to 21%) experienced at least one BSI (179 BSIs in total; bacteraemia 70%, bacterial sepsis 27%, candidaemia 2%). In 57%, the BSI occurred in inpatients, in 79% after conventional chemotherapy. Only 56 % of the patients showed neutropenia at BSI onset. Eventually, patients with acute lymphoblastic leukaemia (ALL) or acute myeloblastic leukaemia (AML), relapsed malignancy and patients with a Broviac faced an increased risk of BSI in the multivariate analysis. Relapsed malignancy (16%) was an independent risk factor for all BSI and for Gram-positive BSI. CONCLUSION: This study confirms relapsed malignancy as an independent risk factor for BSIs in paediatric cancer patients. On a unit level, data on BSIs in this high-risk population derived from prospective surveillance are not only mandatory to decide on empiric antimicrobial treatment but also beneficial in planning and evaluating preventive bundles. WHAT IS KNOWN: • Paediatric cancer patients face an increased risk of nosocomial bloodstream infections (BSIs). • In most cases, these BSIs are associated with the use of a long-term central venous catheter (Broviac, Port), severe and prolonged immunosuppression (e.g. neutropenia) and other chemotherapy-induced alterations of host defence mechanisms (e.g. mucositis). What is New: • This study is the first multicentre study confirming relapsed malignancy as an independent risk factor for BSIs in paediatric cancer patients. • It describes the epidemiology of nosocomial BSI in paediatric cancer patients mainly outside the stem cell transplantation setting during conventional intensive therapy and argues for prospective surveillance programmes to target and evaluate preventive bundle interventions.
UNLABELLED: In a prospective multicentre study of bloodstream infection (BSI) from November 01, 2007 to July 31, 2010, seven paediatric cancer centres (PCC) from Germany and one from Switzerland included 770 paediatric cancerpatients (58% males; median age 8.3 years, interquartile range (IQR) 3.8-14.8 years) comprising 153,193 individual days of surveillance (in- and outpatient days during intensive treatment). Broviac catheters were used in 63% of all patients and Ports in 20%. One hundred forty-two patients (18%; 95% CI 16 to 21%) experienced at least one BSI (179 BSIs in total; bacteraemia 70%, bacterial sepsis 27%, candidaemia 2%). In 57%, the BSI occurred in inpatients, in 79% after conventional chemotherapy. Only 56 % of the patients showed neutropenia at BSI onset. Eventually, patients with acute lymphoblastic leukaemia (ALL) or acute myeloblastic leukaemia (AML), relapsed malignancy and patients with a Broviac faced an increased risk of BSI in the multivariate analysis. Relapsed malignancy (16%) was an independent risk factor for all BSI and for Gram-positive BSI. CONCLUSION: This study confirms relapsed malignancy as an independent risk factor for BSIs in paediatric cancerpatients. On a unit level, data on BSIs in this high-risk population derived from prospective surveillance are not only mandatory to decide on empiric antimicrobial treatment but also beneficial in planning and evaluating preventive bundles. WHAT IS KNOWN: • Paediatric cancerpatients face an increased risk of nosocomial bloodstream infections (BSIs). • In most cases, these BSIs are associated with the use of a long-term central venous catheter (Broviac, Port), severe and prolonged immunosuppression (e.g. neutropenia) and other chemotherapy-induced alterations of host defence mechanisms (e.g. mucositis). What is New: • This study is the first multicentre study confirming relapsed malignancy as an independent risk factor for BSIs in paediatric cancerpatients. • It describes the epidemiology of nosocomial BSI in paediatric cancerpatients mainly outside the stem cell transplantation setting during conventional intensive therapy and argues for prospective surveillance programmes to target and evaluate preventive bundle interventions.
Authors: Roland A Ammann; Nicole Bodmer; Andreas Hirt; Felix K Niggli; David Nadal; Arne Simon; Hulya Ozsahin; Udo Kontny; Thomas Kühne; Maja Beck Popovic; Annette Ridolfi Lüthy; Christoph Aebi Journal: J Clin Oncol Date: 2010-03-15 Impact factor: 44.544
Authors: M Dettenkofer; S Wenzler-Röttele; R Babikir; H Bertz; W Ebner; E Meyer; H Rüden; P Gastmeier; F D Daschner Journal: Clin Infect Dis Date: 2005-03-04 Impact factor: 9.079
Authors: Joanne Lynn; Mary Ann Baily; Melissa Bottrell; Bruce Jennings; Robert J Levine; Frank Davidoff; David Casarett; Janet Corrigan; Ellen Fox; Matthew K Wynia; George J Agich; Margaret O'Kane; Theodore Speroff; Paul Schyve; Paul Batalden; Sean Tunis; Nancy Berlinger; Linda Cronenwett; J Michael Fitzmaurice; Nancy Neveloff Dubler; Brent James Journal: Ann Intern Med Date: 2007-04-16 Impact factor: 25.391
Authors: M Dettenkofer; W Ebner; H Bertz; R Babikir; J Finke; U Frank; H Rüden; F D Daschner Journal: Bone Marrow Transplant Date: 2003-05 Impact factor: 5.483
Authors: Rebekah C Allen; Mark T Holdsworth; Cynthia A Johnson; Cathy M Chavez; Richard L Heideman; Gary Overturf; David Lemon; W Curtis Hunt; Stuart S Winter Journal: Pediatr Blood Cancer Date: 2008-07 Impact factor: 3.167
Authors: D Averbuch; C Avaky; M Harit; P Stepensky; I Fried; T Ben-Ami; V Temper; Y Peled; H Troen; R Masarwa; W Abu Ahmad; M Weintraub; S Revel-Vilk; D Engelhard Journal: Infection Date: 2017-02-15 Impact factor: 3.553
Authors: Sarah Alexander; Brian T Fisher; Aditya H Gaur; Christopher C Dvorak; Doojduen Villa Luna; Ha Dang; Lu Chen; Michael Green; Michael L Nieder; Beth Fisher; L Charles Bailey; John Wiernikowski; Lillian Sung Journal: JAMA Date: 2018-09-11 Impact factor: 56.272